In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Markus Thunecke

Advertisement
Set Alert for Articles By Markus Thunecke

Latest From Markus Thunecke

Methodology: R&D Productivity Ranking

To evaluate the R&D productivity of the world’s 30 largest public pharmaceutical companies, as judged by total pharmaceutical sales, Catenion takes an approach that focuses on value.

BioPharmaceutical

Biopharma R&D Productivity And Growth 2017: Big Pharma Closes The Gap

Catenion updates its annual list of the year's top pharma R&D performers. R&D productivity declined for the first time since 2014. Mid pharmas continue to dominate the top 10, but big pharmas are making inroads.

BioPharmaceutical Research and Development Strategies

Biopharma R&D Productivity And Growth 2016: Innovation Performance Improves

Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth. This year Regeneron shoots to the top and Gilead drops to third place.

Growth Research and Development Strategies

Methodology: R&D Productivity Ranking

To evaluate the R&D productivity of the world’s 30 largest public pharmaceutical companies, as judged by total pharmaceutical sales, Catenion's methodology takes an approach that focuses on value.

BioPharmaceutical

Value-Based R&D Pharma Productivity 2015: Oncology And Hep C Drive Top Performers

Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth.

BioPharmaceutical Research and Development Strategies

Method For Creating Pharma R&D Productivity And Corporate Growth Rankings

Both the ‘Long-Term’ and ‘Momentum’ R&D Productivity rankings include analyst consensus eNPVs of the companies’ pipeline assets. Since eNPVs can only be calculated for ‘visible’ assets, the majority of data is for compounds in Phases II and III.

BioPharmaceutical Research and Development Strategies
See All
Advertisement
UsernamePublicRestriction

Register